8-KItem 7.01 · Reg FD DisclosureItem 9.01 · Financial Statements
Edwards Lifesciences Corp (EW)

Jan 9, 2026 — U.S.

Filed with the SEC on · Summarized by InvestorsBot

Jan 9, 2026 — U.S. District Court (D.C.) granted the FTC’s motion for an injunction blocking Edwards Lifesciences’ proposed acquisition of JenaValve; Edwards will not acquire JenaValve. $EW ⚖️🚫 #Mergers #Antitrust #MedTech

Edwards disclosed the Jan 9 press release in an 8‑K (Item 7.01); Exhibit 99.1 is furnished (not “filed”) under Form 8‑K instructions and is not subject to Section 18 liabilities. $EW 📝🔒 #SEC #MedTech

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from Edwards Lifesciences Corp

Edwards Lifesciences Raises 2026 Guidance After 13.6% Q2 Sales Growth

8-K · July 23, 2026

Edwards filed an 8‑K (Item 9.01) on Feb 10, 2026: Exhibit 99.1 is a press release reporting Q4 2025…

8-K · February 10, 2026

Edwards Lifesciences ($EW) issued a press release on Feb 10, 2026 reporting Q4 2025 financial results; the…

8-K · February 10, 2026

Edwards Lifesciences filed an 8‑K (Item 9.01) on Jan 12, 2026 — Exhibit 99.1: Press Release dated Jan 9,…

8-K · January 12, 2026